Fig. 3.

Impact of both IgG CH1-hinge and Fc on anti-CD40 antibody antitumour activities. MC38 (a, b) and MO4 (c) tumour volumes in FcγR-humanized mice following treatment with control or anti-mCD40 antibodies of indicated constant domains. After tumour cells were subcutaneously inoculated and established in FcγR-humanized mice, mice were treated i.p. twice on day 0 (the day when mice with palpable tumours receive their first treatment) and day 3 with 31.6 μg/mouse of control or anti-CD40 antibodies of indicated constant domains (the N297A mutation abrogates Fc–FcγR binding), and monitored for tumour growth. For mice inoculated with MO4 tumour cells in (c), each treatment also included 2 μg/mouse of DEC-OVA. Shown are tumour growth curves of individual mice (a) or mouse groups (b, c). Numbers of mice: a, b seven to eight mice per group; c seven mice per group except six mice for αmCD40:G2(N297A). Bars represent the mean ± SEM. ^*p ≤ 0.05, ^**p ≤ 0.01, ^***p ≤ 0.001, ^****p ≤ 0.0001, chi-square test (a), and two-way ANOVA with Holm–Sidak’s post hoc (b, c) were used for group comparison. Source data (a–c) are provided as a Source Data file. A representative of two independent experiments is shown (a, b)